FT. LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- MAKO Surgical Corp. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.
All of the offered shares will be sold by MAKO Surgical Corp. The number of shares to be offered and the price range of the offering have not yet been determined. The Company intends to apply to have its common stock approved for quotation on the NASDAQ Global Market under the symbol "MAKO."
J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated will act as joint bookrunners for the offering and Cowen and Company, LLC and Wachovia Capital Markets, LLC will act as co-lead managers. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus for the offering, when available, may be obtained from: J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing email@example.com.
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its
advanced robotic solution and implants for minimally invasive orthopedic
knee procedures. MAKO's Haptic Guidance System(TM) includes an interactive
haptic robotics platform that utilizes tactile-guided robotics and
patient-specific visualization to prepare the knee joint for the insertion
and alignment of resurfacing implants through a keyhole incision. This
FDA-cleared surgeon- interactive haptic robotic system allows surgeons to
provide an innovative tissue-sparing bone resurfacing therapy called
MAKOplasty(TM) to a large, yet underserved patient-specific population
|SOURCE MAKO Surgical Corp.|
Copyright©2007 PR Newswire.
All rights reserved